Price T Rowe Associates Inc Morphic Holding, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$26.12 - $34.07 $8.26 Million - $10.8 Million	-316,399 Reduced 12.54%	2,207,187 $75.2 Million
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $8.02 Million - $12.1 Million	300,958 Added 13.54%	2,523,586 $88.8 Million
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $2.83 Million - $4.4 Million	141,888 Added 6.82%	2,222,628 $64.2 Million
Q3 2023 Nov 14, 2023	SELL	$21.33 - $59.42 $2.38 Million - $6.63 Million	-111,645 Reduced 5.09%	2,080,740 $47.7 Million
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $24.1 Million - $43.6 Million	702,624 Added 47.16%	2,192,385 $126 Million
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $9.36 Million - $17.5 Million	359,764 Added 31.84%	1,489,761 $56.1 Million
Q4 2022 Feb 14, 2023	SELL	$24.14 - $30.37 $235,896 - $296,775	-9,772 Reduced 0.86%	1,129,997 $30.2 Million
Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $2.42 Million - $3.63 Million	-108,791 Reduced 8.71%	1,139,769 $32.3 Million
Q2 2022 Aug 15, 2022	BUY	$19.74 - $43.01 $2.68 Million - $5.85 Million	135,909 Added 12.21%	1,248,560 $27.1 Million
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $1.22 Million - $1.75 Million	-33,710 Reduced 2.94%	1,112,651 $44.7 Million
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $5.46 Million - $8.29 Million	126,142 Added 12.36%	1,146,361 $54.3 Million
Q3 2021 Nov 15, 2021	BUY	$53.61 - $67.5 $34.7 Million - $43.7 Million	646,868 Added 173.26%	1,020,219 $57.8 Million
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $128,349 - $184,831	2,844 Added 0.77%	373,351 $21.4 Million
Q1 2021 May 17, 2021	BUY	$29.77 - $84.85 $11 Million - $31.4 Million	370,507 New	370,507 $23.4 Million

Others Institutions Holding MORF

# of Institutions

Shares Held

4.7M

Call Options Held

Put Options Held

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account